Every 8-K that Radnet (RDNT) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow RDNT and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full RDNT filings page.
RadNet, Inc. filed a prospectus supplement to its automatic shelf registration statement to register for resale up to 34,069 shares of common stock. These shares are to be issued to certain See-Mode Sellers or their designees as the share component of milestone payments under a June 2, 2025 Share Purchase Agreement involving DH AI International Holdings, B.V., a wholly owned RadNet subsidiary. The company also filed a legal opinion from its Chief Legal Officer on the validity of the securities as an exhibit.
RadNet, Inc. reported strong second quarter 2026 growth, with Total Company Revenue of $622.7 million, up 25.0% from $498.2 million a year earlier, and record Adjusted EBITDA of $99.7 million, up 22.7%. Imaging Center segment Adjusted EBITDA margin rose to 16.1%, a 17 basis point improvement, aided by a shift toward higher-value advanced imaging, which grew 21.2% in aggregate and 9.6% on a same-center basis.
The Digital Health segment delivered $32.4 million in revenue, up 56.5%, while Adjusted EBITDA declined to $2.5 million due to increased growth investments. Digital Health Annual Recurring Revenue reached $105.5 million, up from $53.5 million a year earlier. Company cash was $726.3 million at June 30, 2026 and the Net Debt to Adjusted EBITDA Ratio was 1.8x.
GAAP net income attributable to common stockholders was $7.5 million (diluted EPS $0.10), down from $14.5 million ($0.19) in the prior-year quarter, reflecting items such as $6.6 million of acquisition costs and $3.4 million of debt restructuring losses. Adjusted earnings were $23.2 million or $0.29 per diluted share. RadNet raised 2026 Imaging Center guidance for revenue, Adjusted EBITDA and Free Cash Flow while reaffirming Digital Health guidance.
RadNet, Inc. entered into Incremental Amendment No. 3 to its first lien credit and guaranty agreement, securing a new $250.0 million 2026 Incremental Term Loan that is added to its existing term loan facility. The combined Term Loan now matures on April 18, 2031 and carries an interest rate reduced by 0.25% to either Term SOFR plus 2.00% or the alternate base rate plus 1.00%.
Quarterly principal payments on the Term Loan will increase to about $3.1 million, up from roughly $2.4 million. The proceeds are expected to fund future acquisitions, organic expansion, health system partnerships and general corporate purposes. RadNet also reduced the interest rate on its undrawn $282 million revolving credit facility by 0.25%, and highlighted that the new funds supplement a $455 million cash balance as of March 31, 2026 to support its growth strategy.
RadNet, Inc. held its 2026 Annual Meeting of Stockholders, where all four management proposals were approved. Stockholders elected six directors to serve until the 2027 Annual Meeting, with each nominee receiving a substantial majority of votes cast and broker non-votes recorded on each director election.
Quorum was strong, with 73,252,507 shares represented, or approximately 93.58% of the 78,271,515 shares outstanding and eligible to vote as of the April 6, 2026 record date. Stockholders also ratified Ernst & Young LLP as independent auditor for the year ending December 31, 2026.
In addition, stockholders approved, on a non-binding advisory basis, the compensation of the Company’s named executive officers and approved the amendment and restatement of the Company’s Equity Incentive Plan, both with clear affirmative vote margins.
RadNet, Inc. seeks to secure an incremental term loan in the aggregate principal amount of $200 million through an amendment to its Third Amended and Restated First Lien Credit and Guaranty Agreement. If completed, this new borrowing would be added to the existing term loan and would mature on April 18, 2031, matching the current facility’s maturity.
RadNet expects to use the proceeds to fund future acquisitions, organic expansion, health system partnerships and other general corporate purposes to support strategic growth across its imaging center network and technology platforms. The company notes that closing the loan transaction is subject to customary market and other conditions and, if successful, is expected towards the middle of the month.
RadNet, Inc. reported record first quarter 2026 results, with Total Company Revenue of $575.6 million, a 22.1% increase from the first quarter of 2025, and Adjusted EBITDA of $63.3 million, up 36.3%. Growth was driven by advanced imaging volume, with MRI, CT and PET/CT procedures up 19.7% systemwide and same-center advanced imaging volumes up 8.2%.
The Digital Health segment generated revenue of $29.1 million, up 51.5%, while Adjusted EBITDA declined to $1.3 million due to intentional infrastructure investments. Annual Recurring Revenue for Digital Health rose to $96.9 million at March 31, 2026 from $49.8 million a year earlier.
RadNet still posted a net loss attributable to common stockholders of $33.5 million, or $(0.43) per share, improving from a $(0.51) loss per share a year ago. On an adjusted basis, diluted loss per share narrowed to $(0.28) from $(0.34). The company ended the quarter with $455.3 million in cash and a Net Debt to Adjusted EBITDA leverage ratio slightly below 2.0.
On the strategic side, RadNet closed the acquisition of Gleamer SAS to expand its DeepHealth AI portfolio and launched a new imaging joint venture with Trinity Health’s Saint Alphonsus Health System in Boise, Idaho. Reflecting strong trends, RadNet raised 2026 Imaging Center segment guidance, lifting revenue to $2,355–$2,405 million, Adjusted EBITDA to $340–$353 million, and Free Cash Flow to $112–$122 million, while reaffirming all Digital Health guidance ranges.
RadNet, Inc. reports record 2025 results and raises its outlook for 2026. For the fourth quarter of 2025, revenue rose 14.8% year over year to $547.7 million and Adjusted EBITDA(1) grew 16.9% to $87.7 million, driven by strong volume growth in advanced imaging modalities and efficiency gains in imaging centers.
For full-year 2025, revenue increased 11.5% to $2,040.2 million and Adjusted EBITDA(1) reached $300.2 million, though RadNet recorded a net loss attributable to common stockholders of $18.7 million, or $(0.25) per diluted share, versus net income of $0.04 per share in 2024.
The Digital Health segment delivered 2025 revenue of $92.7 million, up 41.1%, with Annual Recurring Revenue(4) of $75.4 million at December 31, 2025. Management highlights accelerating adoption of AI-powered workflow and clinical tools, aided by acquisitions including Gleamer, and expects Digital Health ARR to approach or exceed $140 million by the end of 2026.
RadNet’s 2026 guidance calls for Imaging Center segment revenue of $2.325–$2.375 billion, Adjusted EBITDA(1) of $335–$348 million and free cash flow(2) of $105–$115 million. Digital Health guidance anticipates 45%–55% revenue growth from 2025 levels, supported by new AI products, additional FDA clearances and ongoing infrastructure investment.
RadNet, Inc. has completed an all-cash acquisition of Paris-based radiology AI company Gleamer SAS for up to €230 million, including about €215 million paid at closing and a contingent €15 million tied to future milestones.
Gleamer, with more than 130 professionals and over 700 customer contracts across 44 countries, will be integrated into RadNet’s DeepHealth digital health segment. Combining Gleamer’s multimodality, FDA-cleared and CE-marked AI tools with DeepHealth’s existing portfolio is described as making DeepHealth the largest provider of radiology clinical AI solutions worldwide.
The companies highlight benefits such as automated exam prioritization, draft reporting, and workflow automation across X-ray, CT, MR, mammography and ultrasound. DeepHealth and Gleamer together anticipate annual recurring revenue approaching or exceeding $140 million by the end of 2026, backed by a broad installed base and high recurring-revenue profile.
RadNet, Inc. has registered for resale up to 190,924 shares of its common stock through a prospectus supplement to its automatic shelf registration statement. These shares will be issued to the Cimar Sellers or their designees as the non-cash portion of the consideration for RadNet’s acquisition of all shares in Cimar (UK) Limited, completed on November 10, 2025. The acquisition was executed under a Share Purchase Agreement between the Cimar Sellers and DH AI International Holdings, B.V., RadNet’s wholly owned Dutch subsidiary. RadNet also filed a legal opinion from Reed Smith LLP on the validity of the registered securities as an exhibit.
RadNet, Inc. expanded its executive leadership team and adjusted compensation for key executives. The company promoted Stephen Forthuber to President and Chief Executive Officer, Eastern Operations, and Norman Hames to President and Chief Executive Officer, Western Operations. Mital Patel was promoted to Executive Vice President and Chief Operating Officer.
In connection with these changes and routine compensation updates effective January 1, 2026, the Compensation Committee approved new annual base salaries of $950,000 for Mr. Forthuber, $950,000 for Mr. Hames, and $925,000 for Mr. Patel. The committee also set annual base salaries of $850,000 for Executive Vice President and Chief Financial Officer Mark Stolper and $850,000 for Cornelis Wesdorp, President and Chief Executive Officer, Digital Health. All other terms of their existing employment agreements remain unchanged.
RadNet, Inc. filed a current report to furnish its financial results for the third quarter ended September 30, 2025. On November 9, 2025, the company issued a press release detailing these results, which is included as Exhibit 99.1.
The information in this report and Exhibit 99.1 is being furnished rather than filed under securities laws, which limits certain legal liabilities and how it may be incorporated into other filings. The report is signed on behalf of RadNet by its Chief Financial Officer, Mark Stolper.
RadNet, Inc. filed a prospectus supplement to its automatic shelf registration on Form S-3, registering for resale by selling stockholders up to 59,444 shares of its common stock. The filing states the shares may be sold from time to time by the referenced holders.
The company also filed a legal opinion from Reed Smith LLP covering the validity of the registered securities, included as Exhibit 5.1.
RadNet, Inc. furnished a press release reporting its financial results for the second quarter ended June 30, 2025, with that press release included as Exhibit 99.1 to this Current Report. The filing identifies the disclosure under Item 2.02 (Results of Operations and Financial Condition) and also includes an interactive XBRL cover page as Exhibit 104. The company states the information is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Exchange Act and will not be incorporated by reference into other filings except by specific reference.
Aside from the notice that Q2 2025 results were released, the report contains no financial figures, metrics, or commentary on performance. The report was executed on behalf of the registrant by Mark Stolper, Chief Financial Officer, and confirms the company’s common stock trades as RDNT on NASDAQ. Investors must consult Exhibit 99.1 for the detailed Q2 financial results.